IMR Press / FBL / Volume 20 / Issue 5 / DOI: 10.2741/4344

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Review
The aspartyl (asparaginyl) beta-hydroxylase in carcinomas
Show Less
1 School of Life Sciences, Northwestern Polytechnical University, 710072 Xi’an, China
2 Key Laboratory for Space Bioscience and Biotechnology, Northwestern Polytechnical University, 710072 Xi’an, China
Academic Editor:Wei Qin
Front. Biosci. (Landmark Ed) 2015, 20(5), 902–909;
Published: 1 January 2015
(This article belongs to the Special Issue Pathogenesis and diagnostic modalities in cancer)

Aspartyl-(asparaginyl)-β-hydroxylase (AAH) is a member of the α-ketoglutarate-dependent dioxygenase family that catalyzes the hydroxylation of aspartyl and asparaginyl residues epidermal growth factor (EGF)-like domains of protein. In human tumorous cell lines from main systems of body, including tumor cells of kidney, throat, breast, liver, bladder, cervical and ovary, the AAH can be detected at both the transcriptional level and the translational level, and moreover, the AAH expression is usually increased, which is associated with the development and progression of carcinomas. Thus, AAH may play an important role in different carcinomas and may be a potential hub in carcinogenesis. In this review, we will discuss the role of AAH in carcinomas, focusing on liver cancers and other digestive tumors, lung cancers, and tumors of nervous system.

hepatocellular carcinoma
Back to top